Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update
Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors ADXS-503 Phase 1/2 trial data presented at SITC demonstrated disease control rate of 67% and overall response …